Clinuvel Pharmaceuticals Limited announced a strategic reorganization effective January 1, 2027, that will relocate its corporate headquarters to the United States and reduce its total workforce by 10% to 20%. The company, currently based primarily in Australia, markets SCENESSE, a systemic photoprotective drug approved in the U.S., Europe, Canada, Israel, and Australia for erythropoietic protoporphyria. Clinuvel said the move reflects that a majority of its shareholders are foreign investors, and the U.S. represents over 40% of the global pharmaceutical market by value, offering a primary ecosystem for premium pricing, regulatory advancement, and M&A activity. The relocation is also intended to provide access to deeper and more liquid capital for future financing projects. Clinuvel had been considering a U.S. listing for some time and believes refocusing operations there will yield favorable utilization of its assets.